The New Technology Add on Payment NTAP Program: What Life Sciences Companies Should Know About Medicares Time Limited Program

For biopharmaceutical, medical device and diagnostic manufacturers, navigating market access and reimbursement in the inpatient hospital setting is a challenge in the Medicare program, where most technologies are bundled into an existing payment rate. This bundled payment methodology means that providers often lack incentives to adopt new medical technologies not already reflected in their costs. Since 2001, the Centers for Medicare & Medicaid Services has offered manufacturers of new, groundbreaking technologies the ability to apply for a New Technology Add-on Payment (NTAP) designation for their drug, device or diagnostic that will provide hospitals with extra payments when they use the product for the 2-3 year period after market entry. These add-on payments are often critical in a hospital’s decision to adopt new technologies.

Download program materials here.

View the Foley Hoag and The Moran Company webinar which dissecs the upcoming NTAP application process and addresses frequently asked questions surrounding this time-limited program. Our panelists, who have helped dozens of early-stage and mature life sciences companies apply for and receive NTAP designation for their novel medical technologies, discuss:

  • Assessing whether or not your technology qualifies for NTAP
  • Why some technologies succeed – and others don’t – during the application process
  • The dos and don’ts of engaging with CMS on your application
  • Recent rulemaking changes and trends that have emerged in the NTAP program's first two decades